Exhibit 7： Summary of stakeholder interview responses (n=20) to assess the relative impact of key drivers and barriers influencing biomarker testing adoption in oncology
include things like adjustment of biomarker testing age, line of therapy of when testing should be done, or incorporated into clinical guidelines (e.g., NsCLC, breast cancer), testing implementation remains inconsistent in driver of biomarker adoption, while limited tissue practice. This variability suggests that multiple factors continue to influence testing uptake (Exhibit 7). barrier. Yet, even in tumor types with targeted therapies formally recognized aspart of thestandard work-up.
原图定位
